Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
B

Ratings ESG MSCI

Ratings Sarepta Therapeutics, Inc.: Strengths and Weaknesses

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
Highlights: Sarepta Therapeutics, Inc.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past twelve months, EPS forecast has been revised upwards.
Weaknesses: Sarepta Therapeutics, Inc.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

Sarepta Therapeutics, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Sarepta Therapeutics, Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Sarepta Therapeutics, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Sarepta Therapeutics, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Sarepta Therapeutics, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
226.25Cr
B
243.43Cr -
BB
- -
37Cr - - - - - - -
7.54Cr - - - - - - -
Average 128.43Cr
BB
Weighted average by Cap.
BB
  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. Ratings Sarepta Therapeutics, Inc.